Pharmacokinetics and Safety of Pelacarsen, a GalNAc<sub>3</sub>-Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment.

Clin Transl Sci · 2025 · PMC12478598 · PMID 41021771

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

AUC inf showed an increasing trend with increasing Child‐Pugh score (Figure 4 ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Pharmacokinetics and Safety of Pelacarsen, a GalNAc&lt;sub&gt;3&lt;/sub&gt;-Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment.

The sentences

Pharmacokinetics and Safety of Pelacarsen, a GalNAc<sub>3</sub>-Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment.